CTNI-13. UPDATES ON CLINICAL OUTCOMES AND TUMOR RECURRENCE PATTERNS OF A HUMAN PILOT STUDY ASSESSING EFFICACY OF BELINOSTAT (PXD-101) COMBINING WITH CHEMORADIATION IN TREATING GLIOBLASTOMA

INTRODUCTION: Glioblastoma (GBM) is highly aggressive with poor prognosis. Belinostat is a histone deacetylase inhibitor with blood–brain barrier permeability that has anti-GBM activity and may enhance effects of chemoradiation. Our institution conducted a clinical trial evaluating clinical efficacy...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Neuro Oncol
Autors principals: Xu, Karen, Huang, Vicki, Ramesh, Karthik, Gurbani, Saumya, Schreibmann, Eduard, Weinberg, Brent, Sengupta, Soma, Voloschin, Alfredo, Holdhoff, Matthias, Barker, Peter, Kleinberg, Lawrence, Olson, Jeffrey, Shim, Hyunsuk, Shu, Hui-Kuo
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2020
Matèries:
Clinical Trials: Non-Immunologic
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7650343/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa215.180
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars